EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Recent developments in gonorrhea and pelvic inflammatory disease






Journal of Medicine 14(4): 281-305

Recent developments in gonorrhea and pelvic inflammatory disease

Gonorrhea remains the most commonly reported sexually transmitted infection, with a total of 2-2.5 million cases occurring annually in the United States. The annual incidence of gonococcal and nongonococcal pelvic inflammatory disease (PID) is 600,000-1,000,000 cases, 10-15% of which result in infertility due to bilateral tubal occulusion. PID results from ascending infection with sexually transmitted pathogens or components of the normal vaginal flora, or both. Uncomplicated gonorrhea usually is best treated with a single dose of ampicillin or procaine penicillin G (given with probenecid) or spectinomycin, in each case followed by a 7 day course of tetracycline or doxycycline to eradicate coexisting chlamydial infection. PID, both gonococcal and non-gonococcal, ideally should be treated in the hospital with parenteral antibiotics. Regimens utilizing various combinations of doxycycline, cefoxitin, clindamycin, aminoglyocosides, or metronidazole are recommended. The sexual partners of patients with gonorrhea or with PID (non-gonococcal as well as gonococcal) should be routinely examined and treated.

(PDF 0-2 workdays service: $29.90)

Accession: 006269412

PMID: 6423757



Related references

Intrauterine devices and pelvic inflammatory disease: recent developments. Contraception 36(1): 97-109, 1987

Trends for gonorrhea and pelvic inflammatory disease in England and Wales and for gonorrhea in a defined population. American Journal of Obstetrics and Gynecology 138(7 Pt 2): 901-904, 1980

Gonorrhea chlamydia and pelvic inflammatory disease. Current Opinion in Infectious Diseases 3(1): 10-19, 1990

Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia. Pharmacoepidemiology and Drug Safety 5(6): 409-414, 1996

Diagnosis and treatment of pelvic inflammatory disease and gonorrhea in the emergency department. Jacep 5(11): 888-889, 1976

Do contraceptives influence the incidence of pelvic acute inflammatory disease in women with gonorrhea?. Contraception 20(2): 149-158, 1979

Age specific risks of syphilis gonorrhea and hospitalized pelvic inflammatory disease in sexually experienced usa women. Sexually Transmitted Diseases 11(4): 291-295, 1984

Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. American Journal of Emergency Medicine 30(7): 1114-1117, 2012

Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstetrics and Gynecology 120(6): 1314-1321, 2013

Pelvic inflammatory disease (PID) from Chlamydia trachomatis versus PID from Neisseria gonorrhea: from clinical suspicion to therapy. Giornale Italiano di Dermatologia E Venereologia 147(5): 423-430, 2012